Zenas BioPharma, Inc. (ZBIO) Institutional Ownership

Ownership Summary

Zenas BioPharma, Inc. (NASDAQ:ZBIO) currently has 78 active institutional owners and shareholders as of today (September 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• These investors collectively held 82.6% of the company's total shares outstanding in September 2025, up from 80.7% in June 2025.
• The company experienced a 3.46% quarterly change in institutional shares held, alongside an increase of 81.40% in total owners annually.
• The latest 13F cycle for Zenas BioPharma reveals that of 78 total investors, 34 funds grew their exposure, whereas 24 reduced theirs and 20 made no changes.
• Collectively, institutional investors increased their stake in Zenas BioPharma to 34.77Mn shares as of September 2025, a change that is up by 1.16Mn shares quarter on quarter and up 10.02Mn shares year over year.
• With 4.91Mn shares, SR ONE CAPITAL MANAGEMENT, LP commands the largest institutional position in Zenas BioPharma as of September 30, 2025, equating to 11.66% of the company.
• Among the most significant buyers of Zenas BioPharma during September 2025 were FMR LLC (1.50Mn), VANGUARD GROUP INC (170.55K), Invesco Ltd. (145.80K), BlackRock, Inc. (133.03K), GEODE CAPITAL MANAGEMENT, LLC (96.42K).
• Leading sellers of Zenas BioPharma stock in September 2025 included ArrowMark Colorado Holdings LLC (269.67K), Novo Holdings A/S (250.00K), Eversept Partners, LP (166.74K), PRICE T ROWE ASSOCIATES INC /MD/ (110.90K), MILLENNIUM MANAGEMENT LLC (63.05K).
• The top 10 institutional holders of Zenas BioPharma for the quarter ending September 2025 included SR ONE CAPITAL MANAGEMENT, LP (4.91Mn), FMR LLC (4.82Mn), Enavate Sciences GP, LLC (3.76Mn), NEA Management Company, LLC (2.73Mn), Novo Holdings A/S (2.00Mn), Fairmount Funds Management LLC (1.89Mn), FEDERATED HERMES, INC. (1.86Mn), NVP Associates, LLC (1.84Mn), DEERFIELD MANAGEMENT COMPANY, L.P. (1.56Mn), BlackRock, Inc. (1.23Mn).